High dose hypofractionated proton beam therapy is a safe and feasible treatment for central lung cancer

1Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108. 10.3322/caac.21262TorreLA BrayF SiegelRL FerlayJ Lortet-TieulentJ JemalA. Global cancer statistics, 2012 CA Cancer J Clin 2015 65 87108 10.3322/caac.21262Open DOISearch in Google Scholar

2Fitzmaurice C, Dicker D, Pain A. The global burden of cancer 2013. JAMA Oncol 2015; 1: 505-27. 10.1001/jamaoncol.2015.0735FitzmauriceC DickerD PainA. The global burden of cancer 2013 JAMA Oncol 2015 1 50527 10.1001/jamaoncol.2015.0735Open DOISearch in Google Scholar

3 Li Q, Swanick CW, Allen PK, Gomez DR, Welsh JW, Liao Z, et al. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol 2014; 112: 256-61. 10.1016/j.radonc.2014.07.010LiQ SwanickCW AllenPK GomezDR WelshJW LiaoZ et al. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications Radiother Oncol 2014 112 25661 10.1016/j.radonc.2014.07.010Open DOISearch in Google Scholar

4Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005; 63: 1427-31. 10.1016/j.ijrobp.2005.05.034NagataY TakayamaK MatsuoY NorihisaY MizowakiT SakamotoT et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame Int J Radiat Oncol Biol Phys 2005 63 142731 10.1016/j.ijrobp.2005.05.034Open DOISearch in Google Scholar

5Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys 2015; 93: 989-96. 10.1016/j.ijrobp.2015.07.2278NagataY HiraokaM ShibataT OnishiH KokuboM KarasawaK et al. Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG0403 Int J Radiat Oncol Biol Phys 2015 93 98996 10.1016/j.ijrobp.2015.07.2278Open DOISearch in Google Scholar

6Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015; 16: 630-37. 10.1016/S1470-2045(15)70168-3ChangJY SenanS PaulMA MehranRJ LouieAV BalterP et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials Lancet Oncol 2015 16 63037 10.1016/S1470-2045(15)70168-3Open DOISearch in Google Scholar

7Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006; 24: 4833-9. 10.1200/JCO.2006.07.5937TimmermanR McGarryR YiannoutsosC PapiezL TudorK DeLucaJ et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer J Clin Oncol 2006 24 48339 10.1200/JCO.2006.07.5937Open DOISearch in Google Scholar

8Bush DA, Cheek G, Zaheer S, Wallen J, Mirshahidi H, Katerelos A, et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and perIPFheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys 2013; 86: 964-8. 10.1016/j.ijrobp.2013.05.002BushDA CheekG ZaheerS WallenJ MirshahidiH KaterelosA et al. High-dose hypofractionated proton beam radiation therapy is safe and effective for central and perIPFheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center Int J Radiat Oncol Biol Phys 2013 86 9648 10.1016/j.ijrobp.2013.05.002Open DOISearch in Google Scholar

9Register SP, Zhang X, Mohan R, Chang JY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1015-22. 10.1016/j.ijrobp.2010.03.012RegisterSP ZhangX MohanR ChangJY. Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2011 80 101522 10.1016/j.ijrobp.2010.03.012Open DOISearch in Google Scholar

10Chang JY, Komaki R, Wen HY, De Gracia B, Bluett JB, McAleer MF, et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1350-7. 10.1016/j.ijrobp.2010.04.049ChangJY KomakiR WenHY De GraciaB BluettJB McAleerMF et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer Int J Radiat Oncol Biol Phys 2011 80 13507 10.1016/j.ijrobp.2010.04.049Open DOISearch in Google Scholar

11Nihei K, Ogino T, Ishikura S, Nishimura H. High-dose proton beam therapy for Stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006; 65: 107-111. 10.1016/j.ijrobp.2005.10.031NiheiK OginoT IshikuraS NishimuraH. High-dose proton beam therapy for Stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2006 65 107111 10.1016/j.ijrobp.2005.10.031Open DOISearch in Google Scholar

12Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall-cell lung cancer. Cancer 2011; 117: 4707-13. 10.1002/cncr.26080ChangJY KomakiR LuC WenHY AllenPK TsaoA et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall-cell lung cancer Cancer 2011 117 470713 10.1002/cncr.26080Open DOISearch in Google Scholar

13Kadoya N, Obata Y, Kato T, Kagiya M, Nakamura T, Tomoda T, et al. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 79: 1225-31. 10.1016/j.ijrobp.2010.05.016KadoyaN ObataY KatoT KagiyaM NakamuraT TomodaT et al. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer Int J Radiat Oncol Biol Phys 2011 79 122531 10.1016/j.ijrobp.2010.05.016Open DOISearch in Google Scholar

14Lee CH, Tait D, Nahum AE, Webb S. Comparison of proton therapy and conformal X-ray therapy in non-small cell lung cancer (NSCLC). Br J Radiol 1999; 72: 1078-84. 10.1259/bjr.72.863.10700825LeeCH TaitD NahumAE WebbS. Comparison of proton therapy and conformal X-ray therapy in non-small cell lung cancer (NSCLC) Br J Radiol 1999 72 107884 10.1259/bjr.72.863.10700825Open DOISearch in Google Scholar

15Suit H, Goldberg S, Niemierko A, Trofimov A, Adams J, Paganetti H. Proton beams to replace photon beams in radical dose treatments. Acta Oncol 2003; 42: 800-8. 10.1080/02841860310017676SuitH GoldbergS NiemierkoA TrofimovA AdamsJ PaganettiH. Proton beams to replace photon beams in radical dose treatments Acta Oncol 2003 42 8008 10.1080/02841860310017676Open DOISearch in Google Scholar

16Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47. 10.1016/j.ejca.2008.10.026EisenhauerEA TherasseP BogaertsJ SchwartzLH SargentD FordR et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 2009 45 22847 10.1016/j.ejca.2008.10.026Open DOISearch in Google Scholar

17Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-82. 10.1016/S0959-8049(99)00229-4YoungH BaumR CremeriusU HerholzK HoekstraO LammertsmaAA et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 1999 35 177382 10.1016/S0959-8049(99)00229-4Open DOISearch in Google Scholar

18Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83. 10.1016/0021-9681(87)90171-8CharlsonME PompeiP AlesKL MacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 1987 40 37383 10.1016/0021-9681(87)90171-8Open DOISearch in Google Scholar

19Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-6. 10.1016/0360-3016(95)00060-CCoxJD StetzJ PajakTF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys 1995 31 13416 10.1016/0360-3016(95)00060-COpen DOISearch in Google Scholar

20Song SY, Choi W, Shin SS, Lee SW, Ahn SD, Kim JH, et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer 2009; 66: 89-93. 10.1016/j.lungcan.2008.12.016SongSY ChoiW ShinSS LeeSW AhnSD KimJH et al. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus Lung Cancer 2009 66 8993 10.1016/j.lungcan.2008.12.016Open DOISearch in Google Scholar

21Modh A, Rimner A, Williams E, Foster A, Shah M, Shi W, et al. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2014; 90: 1168-76. 10.1016/j.ijrobp.2014.08.008ModhA RimnerA WilliamsE FosterA ShahM ShiW et al. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy Int J Radiat Oncol Biol Phys 2014 90 116876 10.1016/j.ijrobp.2014.08.008Open DOISearch in Google Scholar

22Chaudhuri AA, Tang C, Binkley MS, Jin M, Wynne JF, von Eyben R, et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. Lung Cancer 2015; 89: 50-6. 10.1016/j.lungcan.2015.04.014ChaudhuriAA TangC BinkleyMS JinM WynneJF von EybenR et al. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors Lung Cancer 2015 89 506 10.1016/j.lungcan.2015.04.014Open DOISearch in Google Scholar

23Tekatli H, Senan S, Dahele M, Slotman BJ, Verbakel WF. Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes. Radiother Oncol 2015; 117: 64-70. 10.1016/j.radonc.2015.09.028TekatliH SenanS DaheleM SlotmanBJ VerbakelWF. Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes Radiother Oncol 2015 117 6470 10.1016/j.radonc.2015.09.028Open DOISearch in Google Scholar

24Mangona VS, Aneese AM, Marina O, Hymas RV, Ionascu D, Robertson JM, et al. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis. Int J Radiat Oncol Biol Phys 2015; 91: 124-32. 10.1016/j.ijrobp.2014.08.345MangonaVS AneeseAM MarinaO HymasRV IonascuD RobertsonJM et al. Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis Int J Radiat Oncol Biol Phys 2015 91 12432 10.1016/j.ijrobp.2014.08.345Open DOISearch in Google Scholar

25Lischalk JW, Malik RM, Collins SP, Collins BT, Matus IA, Anderson ED, et al. Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases. Radiat Oncol 2016; 11: 28. 10.1186/s13014-016-0608-8LischalkJW MalikRM CollinsSP CollinsBT MatusIA AndersonED et al. Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases Radiat Oncol 2016 11 28 10.1186/s13014-016-0608-8Open DOISearch in Google Scholar

26Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N, et al. Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys 2012; 83: e545-9. 10.1016/j.ijrobp.2012.01.018MatsuoY ShibuyaK NakamuraM NarabayashiM SakanakaK UekiN et al. Dose-volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer Int J Radiat Oncol Biol Phys 2012 83 e5459 10.1016/j.ijrobp.2012.01.018Open DOISearch in Google Scholar

27Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2012; 82: 457-62. 10.1016/j.ijrobp.2010.08.056BarrigerRB ForquerJA BrabhamJG AndolinoDL ShapiroRH HendersonMA et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy Int J Radiat Oncol Biol Phys 2012 82 45762 10.1016/j.ijrobp.2010.08.056Open DOISearch in Google Scholar

28Nakayama H, Sugahara S, Tokita M, Satoh H, Tsuboi K, Ishikawa S, et al. Proton beam therapy for patients with medically inoperable stage I nonsmall-cell lung cancer at the university of tsukuba. Int J Radiat Oncol Biol Phys 2010; 78: 467-71. 10.1016/j.ijrobp.2009.07.1707NakayamaH SugaharaS TokitaM SatohH TsuboiK IshikawaS et al. Proton beam therapy for patients with medically inoperable stage I nonsmall-cell lung cancer at the university of tsukuba Int J Radiat Oncol Biol Phys 2010 78 46771 10.1016/j.ijrobp.2009.07.1707Open DOISearch in Google Scholar

29Paul S, Lee PC, Mao J, Isaacs AJ, Sedrakyan A. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ 2016; 354: i3570. 10.1136/bmj.i3570PaulS LeePC MaoJ IsaacsAJ SedrakyanA. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis BMJ 2016 354 i3570 10.1136/bmj.i3570Open DOISearch in Google Scholar